Cambridge Healthtech Institute and Bio-IT World Present the Annual Forum for the Structure-Based Drug Design Community

Share Article

Featuring Keynote from the President's Council of Advisors on Science and Technology Dr. David E. Shaw

Building on the well-established reputation among the SBDD community, this conference is a new attempt to bring to focus the latest informatics tools and high performance computing technology for drug design

Cambridge Healthtech Institute and Bio-IT World is pleased to announce the 11th Annual Structure-Based Drug Design (SBDD) conference to be held on June 8-10, 2011 at the Royal Sonesta Hotel Boston in Cambridge, Massachusetts. This meeting serves as the annual forum for the structure-based drug design community, providing insights on the latest development in computational technology for drug discovery, and puts structure-based molecular approaches into the perspective of targeted therapeutics.

"Building on the well-established reputation among the SBDD community, this conference is a new attempt to bring to focus the latest informatics tools and high performance computing technology for drug design," said Ming Guo, conference producer for Cambridge Healthtech Institute. "We are thrilled with the caliber of our speakers, and anticipate a fascinating, interactive and highly educational event."

This meeting brings together presentations from a preeminent internationally recognized faculty including a keynote presentation by David E. Shaw, Ph.D., who was appointed to the President's Council of Advisors on Science and Technology by President Clinton in 1994 and once again by President Obama in 2009. Dr. Shaw's presentation titled "Millisecond-Long Molecular Dynamics Simulations of Proteins on a Special-Purpose Machine" will take place on Friday, June
10.

The main conference agenda features comprehensive presentations and an exhibit/poster hall that will stimulate dialogue on issues that are most relevant to drug design, such as:

  •     Protein Flexibility
  •     Fully Synthetic Protein-Protein Interaction Inhibitor
  •     Fragment-to-Lead Optimization
  •     High Performance Computing and Collaborative Drug Design
  •     State-of-the-Art Molecular Dynamics Simulations

At the conclusion of day one, delegates are invited to a dinner short course on "Identification of Druggable Sites for Protein-Protein Interaction Targets," to be hosted by Sandor Vajda, Ph.D., Professor, Departments of Biomedical Engineering and Chemistry, Boston University; and, Dima Kozakov, Ph.D., Research Assistant Professor, Departments of Biomedical Engineering, Boston University.

Past attendees of this conference had this to say about their experience at the meeting:

"Some discussions inspired new ideas I am going to try." - - Sr. Research Fellow, Merck

"Some very important principles were highlighted and the best thing was that the speakers could
demonstrate working solutions." -- Computational Chemist, Bayer HealthCare

This conference is co-located with CHI's 9thAnnual Next-Gen Kinase Inhibitors (June 6-8, 2011).
CHI is offering reduced conference registrations to those that register for one or both meetings by March 11, 2011.

For additional information on these conferences, call CHI at 781.972.5400 or visit http://www.healthtech.com/sbd

Writers and editors are invited to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (http://www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech's Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

About Bio-IT World: (http://www.bio-itworld.com)

Part of the Cambridge Healthtech Institute Media Group (http://www.chimediagroup.com),
Bio-IT World magazine is a bimonthly publication that life science and IT/informatics professionals continuously reference to find information, news, and commentary on indispensable technologies and business strategies. Bio-IT World provides outstanding coverage of cutting-edge trends and technologies that impact the management and analysis of life sciences data, including next-generation sequencing, drug discovery, predictive and systems biology, informatics tools, clinical trials, and personalized medicine. Cambridge Healthtech Media Group also hosts daily news and opinion at http://www.bio-itworld.com, a variety of e-newsletters, and a rich compendium of webinars and web symposia. Cambridge Healthtech Media Group is based in Needham, Mass.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme(at)healthtech(dot)com
http://www.healthtech.com/sbd

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tracey Fielding

781-972-5429
Email >